Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (2008)	1/6/2004 12:25:40 PM
From: bob zagorin	Respond to of 3044

from briefing.com 8:41 am PT MLNM color 17.68 -1.33: Morgan Stanley says they have confirmed through several clinical sources that the ongoing Phase II trial for Velcade in colorectal cancer has been halted due to a lack of efficacy; firm says sources indicate that Velcade had virtually no single agent activity in colorectal cancer and it did not contribute significantly as a combination therapy with irinotecan, and they expect the Millennium Pharma to provide a formal update of Velcade solid tumor development early next week at a competitor's conference. Maintains Equal-Weight rating.